Also, CBF‐AML patients with MR mutations primarily clustered in the UAMOCS3 category, yet this did not significantly affect overall survival (P = 0.92), suggesting that MR mutations may not critically alter prognosis as discussed in CBF‐AML in 2022 ELN recommendations [2]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.